Your browser doesn't support javascript.
loading
Development of a Novel Virus-Like Particle Vaccine Platform That Mimics the Immature Form of Alphavirus.
Urakami, Akane; Sakurai, Atsuko; Ishikawa, Momoko; Yap, Moh Lan; Flores-Garcia, Yevel; Haseda, Yasunari; Aoshi, Taiki; Zavala, Fidel P; Rossmann, Michael G; Kuno, Sachiko; Ueno, Ryuji; Akahata, Wataru.
Affiliation
  • Urakami A; VLP Therapeutics, Gaithersburg, Maryland, USA.
  • Sakurai A; VLP Therapeutics, Gaithersburg, Maryland, USA.
  • Ishikawa M; VLP Therapeutics, Gaithersburg, Maryland, USA.
  • Yap ML; Department of Biological Sciences, Purdue University, West Lafayette, Indiana, USA.
  • Flores-Garcia Y; Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.
  • Haseda Y; Vaccine Dynamics Project, BIKEN Innovative Vaccine Research Alliance Laboratories, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan.
  • Aoshi T; Vaccine Dynamics Project, BIKEN Innovative Vaccine Research Alliance Laboratories, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan.
  • Zavala FP; Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.
  • Rossmann MG; Department of Biological Sciences, Purdue University, West Lafayette, Indiana, USA.
  • Kuno S; VLP Therapeutics, Gaithersburg, Maryland, USA.
  • Ueno R; VLP Therapeutics, Gaithersburg, Maryland, USA.
  • Akahata W; VLP Therapeutics, Gaithersburg, Maryland, USA wakahata@vlptherapeutics.com.
Clin Vaccine Immunol ; 24(7)2017 Jul.
Article in En | MEDLINE | ID: mdl-28515133
ABSTRACT
Virus-like particles (VLPs) are noninfectious multiprotein structures that are engineered to self-assemble from viral structural proteins. Here, we developed a novel VLP-based vaccine platform utilizing VLPs from the chikungunya virus. We identified two regions within the envelope protein, a structural component of chikungunya, where foreign antigens can be inserted without compromising VLP structure. Our VLP displays 480 copious copies of an inserted antigen on the VLP surface in a highly symmetric manner and is thus capable of inducing strong immune responses against any inserted antigen. Furthermore, by mimicking the structure of the immature form of the virus, we altered our VLP's in vivo dynamics and enhanced its immunogenicity. We used the circumsporozoite protein (CSP) of the Plasmodium falciparum malaria parasite as an antigen and demonstrated that our VLP-based vaccine elicits strong immune responses against CSP in animals. The sera from immunized monkeys protected mice from malaria infection. Likewise, mice vaccinated with P. yoelii CSP-containing VLPs were protected from an infectious sporozoite challenge. Hence, our uniquely engineered VLP platform can serve as a blueprint for the development of vaccines against other pathogens and diseases.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Drug Carriers / Protozoan Proteins / Chikungunya virus / Malaria Vaccines / Vaccines, Virus-Like Particle / Malaria Limits: Animals Language: En Journal: Clin Vaccine Immunol Journal subject: ALERGIA E IMUNOLOGIA / TECNICAS E PROCEDIMENTOS DE LABORATORIO Year: 2017 Type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Drug Carriers / Protozoan Proteins / Chikungunya virus / Malaria Vaccines / Vaccines, Virus-Like Particle / Malaria Limits: Animals Language: En Journal: Clin Vaccine Immunol Journal subject: ALERGIA E IMUNOLOGIA / TECNICAS E PROCEDIMENTOS DE LABORATORIO Year: 2017 Type: Article Affiliation country: United States